Log in

ASX:HMDHeramed Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.11
50-Day Range
MA: A$0.12
52-Week Range
Now: A$0.11
Volume98,572 shs
Average VolumeN/A
Market Capitalization$10.91 million
P/E RatioN/A
Dividend YieldN/A
HeraMED Limited develops and sells pregnancy monitoring solutions for home and professional use in Australia, Europe, and Israel. The company's product is the HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus' heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has co-development agreement with Mayo Clinic for developing platform for pregnancy homecare. HeraMED Limited was founded in 2011 and is based in West Perth, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices
Phone61 8 6189 1155



Sales & Book Value

Annual Sales$145,389.00
Cash FlowA$0.02 per share
Book ValueA$0.02 per share



Market Cap$10.91 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HMD News and Ratings via Email

Sign-up to receive the latest news and ratings for HMD and its competitors with MarketBeat's FREE daily newsletter.

Heramed (ASX:HMD) Frequently Asked Questions

How has Heramed's stock been impacted by COVID-19 (Coronavirus)?

Heramed's stock was trading at A$0.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HMD shares have increased by 23.5% and is now trading at A$0.11. View which stocks have been most impacted by Coronavirus.

Has Heramed been receiving favorable news coverage?

Media coverage about HMD stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heramed earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutHeramed.

Who are some of Heramed's key competitors?

Who are Heramed's key executives?

Heramed's management team includes the following people:
  • Mr. David Groberman, Co-Founder, CEO & Exec. Director
  • Mr. Tal Slonim, Co-Founder, COO & Exec. Director
  • Ms. Sivan Sadan, Chief Financial Officer
  • Mr. Michael Nenner, C.T.O.
  • Henry Jordan, Head of Investor Relations

What is Heramed's stock symbol?

Heramed trades on the ASX under the ticker symbol "HMD."

What is Heramed's stock price today?

One share of HMD stock can currently be purchased for approximately A$0.11.

How big of a company is Heramed?

Heramed has a market capitalization of $10.91 million and generates $145,389.00 in revenue each year.

What is Heramed's official website?

The official website for Heramed is www.hera-med.com.

How can I contact Heramed?

The company can be reached via phone at 61 8 6189 1155.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.